Market Size of Biopreservation Industry
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| CAGR | 15.30 % |
| Fastest Growing Market | Asia-Pacific |
| Largest Market | North America |
| Market Concentration | Medium |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Biopreservation Market Analysis
The biopreservation market is expected to register a CAGR of 15.3% during the forecast period.
The impact of COVID-19 was significant owing to the increased research and development activities of pharmaceutical and biotech companies to prepare and manufacture a vaccine, which required biopreservation. For instance, an article published in Stem Cells Translational Medicine Journal stated that the pandemic resulted in the USFDA approving EUA for three mRNA vaccines that Pfizer-BioNTech manufactured in December 2020, Moderna in December 2020, and Janssen in February 2021. The shipping and storage requirements for these vaccines (ultra-cold vs. refrigerated) necessitated bioprocessing methods. Thus, the COVID-19 pandemic is expected to impact the market significantly.
Biopreservation has broad public health and socio-economic impacts, and it is affecting many lives across the world. It has been widely used to preserve cells and tissues, targeting its reproductive medicine and organ transplantation applications. Stem cell banking and gene banking have also gained global popularity.
Factors driving the market growth include improving healthcare expenditure, adopting in-house sample storage in hospitals and labs, and increasing research and development investment.
Biopreservation is crucial in evolving regenerative medicine. The rise in funding by companies to support biopreservation-based pharmaceutical companies to fulfill the growing demand for tissue and cell preservation is likely to propel market growth. For instance, in December 2021, X-Therma Inc., a biotechnology startup creating technology for regenerative medicine and organ preservation, closed an oversubscribed USD 13 million Series A funding round. The financing was being handled by the entrepreneur-run investment company LOREA AG, with participation from notable return angel investors as well as Zen11 Holdings, Graphene Ventures, VU Venture Partners, Methuselah Foundation, and a few others.
Also, in January 2022, Ori Biotech launched a cell and gene therapy platform after securing over USD 100 million in Series B funding. The interest of entrepreneurs and pharmaceutical companies in investing in a biopreservation company is likely to propel market growth.
Additionally, advancements in technology, increasing product approvals, partnerships, and acquisitions by key players, are helping in the market growth. For instance, in February 2022, Guy's and St Thomas', United Kingdom, launched a fertility preservation service for ovarian tissue cryopreservation for women undergoing cancer treatment. Growing technological advancements and launches in biopreservation, along with the cost-effectiveness of these instruments, are expected to create lucrative opportunities for the target market growth in the given timeframe.
However, the high cost of the instruments and their maintenance and the possibility of tissue injury during preservation is likely to impede the market growth.
